<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369853">
  <stage>Registered</stage>
  <submitdate>5/01/2016</submitdate>
  <approvaldate>4/02/2016</approvaldate>
  <actrnumber>ACTRN12616000129482</actrnumber>
  <trial_identification>
    <studytitle>Adoptive Immunotherapy for Liver Cancer</studytitle>
    <scientifictitle> Survival after T cell receptor-redirected autologous T cell therapy against relapsed hepatitis B virus-induced hepatocellular carcinoma in a liver transplanted patient.</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>Nil</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatocellular carcinoma</healthcondition>
    <healthcondition>Hepatitis B virus</healthcondition>
    <healthcondition>Liver Transplant</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>8 infusions at 7 day intervals of increasing doses of  10,000 (1 infusion), 100,000 (1 infusion),  1,000,000 (1 infusion) and 5,000,000 (5 infusions) cells /kg of autologous t cell receptor-redirected T cells that recognise a hepatitis B virus envelope peptide (FLGPLLVLQA) presented by HLA-Cw*0801. The cells will be prepared in the New Zealand Liver Transplant Research laboratory at Auckland City Hospital and administered by IV infusion by nursing staff.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Survival</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor mass will be assessed after the 4th and 8th infusions by MRI and PET scan.</outcome>
      <timepoint> Assessed after the 4th and 8th infusions. </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Relapsed post-transplant hepatocellular carcinoma</inclusivecriteria>
    <inclusiveminage>21</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Significant psychiatric disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Nil</concealment>
    <sequence>Nil</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods>Nil</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 0</phase>
    <anticipatedstartdate />
    <actualstartdate>5/01/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate>5/01/2016</actualenddate>
    <samplesize>1</samplesize>
    <actualsamplesize>1</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/10/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Duke-Nus Medical School </primarysponsorname>
    <primarysponsoraddress>Duke-NUS Graduate Medical School 
8 College Road, Singapore 169857 
</primarysponsoraddress>
    <primarysponsorcountry>Singapore</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Duke-Nus Medical School </fundingname>
      <fundingaddress>Duke-NUS Graduate Medical School 
8 College Road, Singapore 169857 
</fundingaddress>
      <fundingcountry>Singapore</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Auckland City Hospital</sponsorname>
      <sponsoraddress>Private Bag 92-024, Auckland, 1142.</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This protocol describes the production of autologous, ex vivo-activated, Hepatitis B Virus (HBV) envelope gene specific, T cell receptor (TCR) redirected-T lymphocytes for re-infusion into a patient with HBV-induced hepatocellular carcinoma (HCC) that has relapsed following liver transplantation. Using current protocols, this patient can now only be offered palliative therapy. An  immunological therapy based on adoptive transfer of HBV-specific T cells targeting HBV expressing HCC cells can potentially kill tumor cells while sparing normal tissue. The ability of T cells to specifically recognize cancer cells expressing specific antigens has been the basis of immunlogical therapies with TCR-modified T cells that have been successful in malignancies such as B cell lymphoma (N Engl J Med 2011;365:725-733) and melanoma (Science 2015;348:62-68). Here we propose to treat a patient with a relapse of HBV-induced HCC with T cells that have been engineered to express an envelope gene-specific TCR. These TCR-redirected T cells should exclusively recognize the HCC but not normal liver hepatocytes. 
.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Central Health and Disability Ethics Committee.</ethicname>
      <ethicaddress>Health and Disability Ethics Committees
Ministry of Health
Freyberg Building
20 Aitken Street
PO Box 5013
Wellington
6011</ethicaddress>
      <ethicapprovaldate>18/12/2015</ethicapprovaldate>
      <hrec>15/CEN/217</hrec>
      <ethicsubmitdate>1/12/2015</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>William Abbott</name>
      <address>New Zealand Liver Transplant Unit
Auckland City Hospital
Private Bag 92024
Auckland 1142</address>
      <phone>+64275483711</phone>
      <fax />
      <email>wabbott@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>William Abbott</name>
      <address>New Zealand Liver Transplant Unit
Auckland City Hospital
Private Bag 92024
Auckland 1142</address>
      <phone>+64275483711</phone>
      <fax />
      <email>wabbott@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>William Abbott</name>
      <address>New Zealand Liver Transplant Unit
Auckland City Hospital
Private Bag 92024
Auckland 1142</address>
      <phone>+64275483711</phone>
      <fax />
      <email>wabbott@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>William Abbott</name>
      <address />
      <phone>+64275483711</phone>
      <fax />
      <email>wabbott@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>